Compare EEX & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEX | AMPH |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | 821 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 890.6M | 971.8M |
| IPO Year | N/A | 2005 |
| Metric | EEX | AMPH |
|---|---|---|
| Price | $4.99 | $18.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $7.70 | ★ $28.38 |
| AVG Volume (30 Days) | ★ 714.2K | 710.6K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | $7.49 | $6.90 |
| Revenue Next Year | $6.81 | $4.64 |
| P/E Ratio | $236.96 | ★ $137.93 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.32 | $16.65 |
| 52 Week High | $5.45 | $31.26 |
| Indicator | EEX | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 44.87 |
| Support Level | $4.81 | $16.84 |
| Resistance Level | $5.09 | $20.08 |
| Average True Range (ATR) | 0.03 | 0.80 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 13.65 | 73.53 |
Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States, with operations in the United Kingdom (U.K.), France, and other markets. The company is engaged in three complementary business lines: Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division provides B2B e-commerce and digital merchandising solutions to manufacturers and retailers. Emerald's key revenue is derived from the Connections business, its only reportable segment.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.